NCT05468697 2026-01-23
MK-6482-024
Merck Sharp & Dohme LLC
Phase 1/2 Active not recruiting
Clinical Trials
8 trialsNCT06234605 2026-01-15
A Study of HC-7366 in Combination With Belzutifan (WELIREGâ„¢) in Patients With Renal Cell Carcinoma
HiberCell, Inc.
Phase 1 Recruiting
NCT05030506 2025-12-18
MK-6482-010
Merck Sharp & Dohme LLC
Phase 1 Active not recruiting
NCT02974738 2025-07-10
MK-6482-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting
NCT04195750 2025-04-29
A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT04489771 2025-02-11
MK-6482-013
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT03634540 2024-12-20
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2 Active not recruiting
NCT02293980 2024-06-17
MK-3795-001
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 1 Active not recruiting